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ABSTRAK
Tujuan: menilai imunogenisitas dan keamanan CYD-tetravalent dengue vaccine (CYD-TDV) pada anak.
Metode: pencarian literatur dilakukan pada beberapa database. Studi randomized controlled trials pada anak 
yang divaksinasi dengan CYD-TDV dipilih berdasarkan kriteria inklusi dan ekslusi. Data yang diperoleh dari 
studi tersebut mencakup keamanan, serta imunogenisitas, dalam kaitanya dengan Geometric Mean Titres (GMT) 
dari antibodi. Hasil: enam percobaan klinis dipilih berdasarkan kriteria yang telah ditentukan. Angka GMT 
diperoleh menggunakan 50% Plaque Reduction Neutralization Test (PRNT), sedangkan keamanan diuji secara 
semi-kuantitatif berdasarkan penilaian efek samping. Pengolahan data lebih lanjut dilakukan untuk membandingkan 
hasil dari berbagai studi. Imunogenisitas pada kelompok yang divaksinasi dengan CYD-TDV lebih tinggi dibanding 
kelompok kontrol. Hasil dari semua studi menunjukkan bahwa vaksin cukup aman, efek samping yang berat tidak 
terkait dengan vaksin yang diberikan. Kesimpulan: vaksin CYD-TDV efektif dan aman untuk pasien pada daerah 
endemik. Kesimpulan ini merupakan dasar untuk pengembangan vaksin lebih lanjut, serta penelitian skala besar 
untuk menguji kemampuan vaksin ini dalam mengurangi prevalensi dengue, serta implementasinya pada negara-
negara endemik, seperti Indonesia.
Kata kunci: dengue, imunogenisitas, keamanan, CYD-tetravalent dengue vaccine, vaksin.
ABSTRACT
Aim: to assess the immunogenicity and safety of CYD-tetravalent dengue vaccine (CYD-TDV) in children. 
Methods: comprehensive literature searches were conducted on various databases. Randomized-controlled trials 
on children with CYD-TDV as intervention were selected based on inclusion and exclusion criteria. Data extracted 
from selected trials included safety of vaccine and immunogenicity in terms of Geometric Mean Titres (GMT) of 
antibodies. Results:  six clinical trials were selected based on preset criteria. GMT values were obtained using 
50% Plaque Reduction Neutralization Test (PRNT) and safety was semi-quantitatively assessed based on adverse 
effects. Additional data processing was done to obtain a better understanding on the trends among the studies. The 
results showed that the groups vaccinated with CYD-TDV showed higher immunogenicity against dengue virus 
antigens than the control groups. Safety results were satisfactory in all trials, and most severe side effects were 
unrelated to the vaccine. Conclusion: CYD-TDV is both effective and safe for patients in endemic regions. This 
gives promise for further development and large-scale research on this vaccine to assess its efficacy in decreasing 
dengue prevalence, and its pervasive implementation in endemic countries, such as Indonesia.
Keywords: dengue, immunogenicity, safety, CYD-TDV, vaccine.
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INTRODUCTION
Dengue disease is caused by one of the 
four serotypes of dengue virus, namely DENV-
1, DENV-2, DENV-3, and DENV-4. The 
transmission of the four serotypes is arthropod-
borne, with the main vector being the mosquito 
Aedes aegypti. Most of the infections of dengue 
virus are asymptomatic, but infections can also 
cause diseases ranging from a mild fever to 
a shock syndrome, which can be lethal. Even 
though infection with one serotype provides 
immunity against it for life, disease can 
subsequently be caused again by other serotypes 
in later life.1 In recent decades, the incidence 
of dengue has increased dramatically across 
the world. An epidemiological study estimates 
that 3.9 billion people from 128 countries are 
at risk of infection with dengue viruses.2 One 
recent estimate reports that there are 390 million 
dengue infections per year, of which 96 million 
cases progress to manifest clinically.3
Currently, vector control has been the main 
strategy in managing dengue. According to WHO, 
countries should adopt an integrated management 
approach to vector control in order to optimize 
the use of resources, efficacy, cost effectiveness, 
ecological safety and sustainability.4 Current 
control measures target different stages of 
development of A. aegypti.5 For example, in 
Indonesia, dengue prevention is carried out 
through both vector control and early warning 
system.6 Vector control includes source reduction 
and elimination of adult mosquitos. The source 
reduction program is commonly known as “3M 
– Menguras, Menutup dan Mengubur” which 
means to drain, to close and to bury potential 
breeding sites of dengue. Additional methods 
include the utilization of larvacide powder, and 
controlling lighting and ventilation in the house.7
Despite all the existing vector control 
measures, the global spread of the disease still 
persists.4 This calls for a more urgent need to 
introduce a vaccine into the prevention scheme. 
When integrated with the current vector control, 
a safe, efficacious and cost-effective vaccine has 
the potential to significantly improve dengue 
prevention.
Several dengue vaccines have been developed 
in the past. However, the one that has shown 
most promise is the CYD-TDV (Trade name: 
Dengvaxia), which is a Tetravalent Dengue 
Vaccine developed by Sanofi Pasteur. This is a 
live-attenuated chimeric vaccine that contains 
all four dengue virus antigens (DENV 1-4) with 
a yellow fever backbone. WHO recommends 
the introduction of this vaccine in areas where 
there is a high burden of dengue disease.8 As of 
April 2016, CYD-TDV has been licensed only in 
Mexico, Brazil, El Salvador, Paraguay, and the 
Philippines.9 Nevertheless, due the novelty of this 
vaccine, more evidence on its safety and efficacy 
is required before it can be widely approved. This 
review aims to discuss whether the CYD-TDV is 
a viable preventive measure for Dengue through 
a systematic review by assessing its efficacy (in 




A comprehensive literature search was 
conducted in October 2016 using the databases 
PubMed, The Cochrane Library, Scopus, 
ProQuest, EBSCOhost, and Science Direct. 
The combinations of terms used for the search 
included “Tetravalent Dengue Vaccine”, “CYD-
TDV”, “children”, and “immunogenicity”. 
Where applicable and available, appropriate 
advance search techniques were applied to 
narrow the search.
Selection of Trials
Inclusion and exclusion criteria were set 
prior to selection of trials. The inclusion criteria 
used to select the studies for this article are based 
on the PICOS formula. The population included 
in this study are healthy subjects aged between 2 
to 18 years old. The intervention used in all trials 
must be a 3-dose regimen of CYD-TDV. Studies 
must also have a group of patients receiving 
placebo as control for comparison. The outcomes 
measured are humoral immunogenicity and 
safety of CYD-TDV. Study designs included 
in this review are all randomized-control trials. 
Studies that mixed subjects of all age groups 
in the same treatment group, or studies that 
did not measure the baseline characteristics of 
patients were excluded.
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Data Extraction
For each selected trial, information about 
study design and data for immunogenicity 
(hence efficacy) and safety of CYD-TDV will 
be extracted. Study design includes population 
characteristics (age, region, sample size, baseline 
seropositivity - Baseline seropositivity refers to 
the percentage of the population that has antibody 
titers ≥10 1/dil for any one of the four dengue 
serologies (measured using Plaque Reduction 
Neutralization Test)), intervention, control, 
and outcome measurements. Immunogenicity 
is measured by using data of Geometric Mean 
Titers of neutralizing antibodies against DENV 
1, DENV 2, DENV 3, and DENV 4 at baseline 
and after each dose of CYD-TDV and control. 
Safety is evaluated by the authors’ reports on 
adverse reactions and safety profile of CYD-
TDV as compared to control injections.
Quality Assessment
The quality of included studies was assessed 
using “Quality Assessment of Controlled 
Intervention Studies”10 developed by The 
National Heart, Lung, and Blood Institute 
(NHLBI) and Research Triangle Institute 
International Jointly. It includes 14 criteria that 
need to be assessed, which refer to the internal 
validity of each of the included studies based on 
their methodology. All of the criteria were scored 
with either yes, no, Cannot Determine (CD), or 
Not Applicable (NA). A “yes” was given one 
point, whereas a “no” was given a score of 0.
No standard for a good, moderate, or poor 
study was given. Hence, a study obtaining a 
score of 11/14 or higher was defined as a good 
quality study, meanwhile studies receiving a score 
of 7/14 or less were defined as poor studies. A 
score between 7 and 11 out of 14 was defined as 
moderate.
Two reviewers (RA, OEY) independently 
analyzed the included studies based on the 
quality assessment criteria. If the ratings 
differed, the articles were discussed until a 
common consensus was reached.
RESULTS
The search terms were applied to all of the 6 
search engines and databases mentioned earlier. 
Titles and abstracts were screened and relevant 
titles were selected. After removal of duplicates, 
a total of 61 studies were obtained from the 
database search. Initial screening of abstracts 
against eligibility criteria excluded 41 studies. A 
further 14 trials were excluded after reading full 
text articles as they did not have a viable study 
design based on preset inclusion and exclusion 
criteria. The comprehensive data on the study 
selection process can be seen in Figure 1.
The six clinical trials selected in this 
systematic review were conducted by Dayan, et 
al. (2013),11 Amar-Singh, et al. (2013),12 Lanata, 
et al (2012),13 Sabchareon, et al (2012),14 Villar, 
et al (2013),15 and Leo, et al (2012).16
Quality of the Included Studies
Quality assessment (as seen in the table in 
the appendix) showed that all 6 studies were 
defined as good quality studies. The results of 
the quality assessment done for all included 
studies reflects any possibilities of bias or other 
weaknesses in the study designs. In the study 
conducted by Leo et al.16, there was only single 
blinding. This is because the placebo used for 
the 2nd and 3rd doses included an intramuscular 
Hepatitis A vaccine (as described under “Study 
Designs and Characteristics”), whereas CYD-
TDV is administered subcutaneously. Hence, 
the investigators could differentiate between 
the control and intervention groups based on 
the route of delivery. This could be a possible 
source of bias.
Other than this, because of the long time 
period of the regimen (6 months for 3 doses), 
none of the studies could control exposure of 
subjects to dengue antigens outside of the study 
(ex: from the environment). Such exposure could 
be immunogenic independent of the effects of the 
vaccine, hence acting as a potential confounding 
factor. However, this is insignificant due to the 
large sample size of the trials.
Other than these, all studies fulfilled the 
criteria in the quality assessment tool, and hence 
had good internal validity.
Study Designs and Characteristics
Table 1 provides the summary of the study 
design of all of the included studies. All of 
the studies applied a similar study design, and 
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hence can be compared reliably. There are 
some differences in the control group of the 
studies, as some use 0.9% NaCl and others use 
other vaccines. However, we consider that this 
does not significantly affect the results as none 
of the control vaccines contain antigens of 
Dengue Virus. The study conducted by Leo et 
al.16 separated the data for different age groups, 
hence the data will be presented separately in 
tables and charts.
Study Outcome: Efficacy of Intervention
The efficacy of CYD-TDV was primarily 
measured by analyzing the immunogenicity of 
the interventions, indicated by the geometric 
mean titers (GMT) of neutralizing antibodies 
(antibody titer) against each of the four antigens 
(DENV-1, DENV-2, DENV-3, DENV-4). The 
GMT represents the average antibody titer in a 
population of people.
Plaque reduction neutralization test (PRNT) 
was used to quantify the titer of antibodies in all 
trials. The data is represented in Figure 2.
The data is extracted for GMTs of antibodies 
against each antigen at baseline, after dose 2, and 
after dose 3 of both test and control groups in 
all 6 trials (except for the study by Leo et al.16 
which only presented data for immunogenicity 
at baseline and post-dose 3).
In order to improve the analysis of the trend, 
the fold increase in GMTs from baseline to post-
dose three were calculated for all 4 antigens in 
all studies for both test and control groups. This 
data can be seen in Figure 3.
We also collected data for the peak of GMT 
values in test groups of all trials. This represents 
the highest GMT value recorded for the test 
groups for all serology tests either at baseline, 
after dose 2, or after dose 3. These results would 
Figure 1. Flow chart of search strategy
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Table 1. The summary of experimental designs of the six studies
Study Population Intervention Control Outcome Measures







69% in test group
71% in control group
Three doses of 






Three doses of NaCl 
0.9% at 0, 6, and 12 
months
Enrollment and 
Dropout: 50 enrolled, 
46 completed
Efficacy: Immunogenicity 
against DENV 1-4 measured 
at baseline and 28 days after 
each dose using PRNT50 and 
calculation of GMT
Safety: Unsolicited systemic 
reaction, solicited injection site 
reactions, solicited systemic 
reactions, and Serious Adverse 
Effects (SAEs) were recorded
Amar-







44.9% in test group
48% in control group
Three doses of 






Three doses of placebo 
at 0, 6, and 12 months
Enrollment and 
Dropout: 51 enrolled, 
50 completed
Efficacy: Immunogenicity 
against DENV 1-4 measured 
at baseline and 28 days after 
dose 2 and 3 using PRNT50 
and calculation of GMT
Safety: Unsolicited systemic 
reaction, solicited injection site 
reactions, solicited systemic 
reactions, and Serious Adverse 
Effects (SAEs) were recorded







37.2% in test group
48.5% in control group
Three doses of 






Two doses of placebo 




Dropout: 100 enrolled, 
90 completed
Efficacy Immunogenicity 
against DENV 1-4 measured 
at baseline and 28 days after 
dose 2 and 3 using PRNT50 
and calculation of GMT
Safety: Unsolicited systemic 
reaction, solicited injection site 
reactions, solicited systemic 
reactions, and Serious Adverse 








70% in test group
68% in control group
Three doses of 






Three doses of NaCl 
0.9% at 0, 6, and 12 
months
Enrollment and 
Dropout: 99 enrolled, 
48 completed
Efficacy: Immunogenicity 
against DENV 1-4 measured 
at baseline and 28 days after 
each dose using PRNT50 and 
calculation of GMT
Safety: Unsolicited systemic 
reaction, solicited injection site 
reactions, solicited systemic 
reactions, and Serious Adverse 
Effects (SAEs) were recorded







75.1% in test group
77.9% in control group
Three doses of 






Two doses of NaCl 
0.9% at 0 and 6 
months, and a dose of 
DPT at 12 months
Enrollment and 
Dropout: 199 enrolled, 
180 completed
Efficacy: Immunogenicity 
against DENV 1-4 measured 
at baseline and 28 days after 
each dose using PRNT50 and 
calculation of GMT
Safety: Unsolicited systemic 
reaction, solicited injection site 
reactions, solicited systemic 
reactions, and Serious Adverse 
Effects (SAEs) were recorded
Leo, et al 
(2013)16
Age: 2-45 (results were 
separated for all age 







16.6% in test group
20.8% in control group
Three doses of 
CYD-TDV at 0, 6, 
and 12 months
Enrollment:
236 enrolled (2-11 
y.o)
141 enrolled (12-17 
y.o)
93% pts completed 
the trial
One dose of NaCl 0.9% 
at 0 months, followed 
by two doses of either 
Hep-A or Influenza 
vaccines at months 6 
and 12 (based on age)
Enrollment:
80 enrolled (2-11 y.o)
46 enrolled (12-17 y.o)
92% pts completed 
the trial
Efficacy: Immunogenicity 
against DENV 1-4 measured 
at baseline and 28 days after 
third dose using PRNT50 and 
calculation of GMT
Safety: Unsolicited systemic 
reaction, solicited injection site 
reactions, solicited systemic 
reactions, and Serious Adverse 
Effects (SAEs) were recorded
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help us to compare immune responses against 
CYD-TDV in different trials. This data can be 
seen in Figure 4.
Study Outcome: Safety of Intervention
All of the studies collected data for unsolicited 
systemic reactions, solicited injection-site 
Figure 2. Geometric mean titers (1/dil) of neutralizing antibodies against DENV 1-4 in test and control groups
Figure 3. Fold increase in geometric mean titres of each serotype from baseline to the end of third dose
reactions, solicited systemic reactions, and severe 
adverse effects. Additionally, any immediate AEs 
that occurred within 30 minutes of injections were 
observed (except for Lanata et al.13).
Solicited injection-site reactions include 
erythema, swelling, and pain, among others, 
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and were observed for up to 7 days after the 
injections in all trials. Solicited systemic 
reactions are systemic reactions which are 
expected from the injections, and include fever, 
headache, malaise, myalgia, and myasthenia, and 
were observed for up to 14 days after injections. 
Unsolicited systemic reactions are any systemic 
reactions in response to the vaccine that are 
not expected, and were observed for up to 28 
days after each injection in all trials. Severe 
adverse effects were any serious illnesses or 
reactions contracted during the course of the 
trial that needed hospitalization. This included 
symptomatic dengue disease. All of the trials 
graded solicited and unsolicited reactions 
from 1-3. The data for safety of the vaccine is 
presented semi-quantitatively in Table 2.
DISCUSSION
Immunogenicity in trials was analyzed 
by fold increase of Geometric Mean Titer 
from baseline to post dose 3 (Figure 3). The 
fold increase of all antibody titers in patients 
injected with CYD-TDV vaccine is larger when 
compared to control groups in all trials. For 
example, in Amar-Singh et al.12, the antibody 
titer against DENV3 increased 12.37 fold in test 
group and only 1.03 in control group. This trend 
is seen across all trials for antibodies against all 
4 antigens. This is attributed to the tetravalent 
nature of this vaccine, which is capable of 
inducing a humoral immune response for all four 
serotypes of the dengue virus. This indicates that 
the CYD-TDV is more effective in eliciting a 
protective immune response against the dengue 
infection.
Another trend common to test groups in 
all trials is that the antibody titers reached high 
levels after dose 2, but the subsequent dose (dose 
3) failed to increase it further substantially. This 
presents as a plateau-shaped pattern in Figure 
2. In Amar-Singh et al,12 the GMT for DENV 
1 antibody increased from 15.3 at baseline, to 
119.0 post dose 2, which is an increase of 103.7 
However, at the end of dose 3, the GMT only 
reached 151.0, which is a meagre increase of 
32.0 from post dose 2. This trend is consistent 
in all trials, as seen in Figure 2.
This plateau pattern implies that 2 doses 
of CYD-TDV vaccine are more immunogenic, 
hence more effective, than the third dose. 
However, the three dose regimen is still 
supported. Observations from some trials12, 13,15 
stated that the third dose significantly increased 
GMT levels in patients who were flavivirus 
seronegative at baseline, but not in patients 
who were flavivirus-seropositive at baseline. 
This means that the third dose is still effective 
for previously flavivirus seronegative patients. 
Moreover, in a clinical setting, it is impractical 
to assess antigen seropositivity before vaccine 
administration. Therefore, it is still most efficient 
to standardize a three dose regimen for this 
vaccination.
Figure 4. The peak of GMT values (1/dil) in test groups of all trials
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Finally, we also observed that the magnitude 
of immune response in test groups is different 
between studies, as some studies show more 
robust immune responses than others. We can 
compare the strength of immune responses in 
each study by comparing the peak antibody titers 
(GMT) recorded (Figure 4). In all 4 serologies, 
the highest and second highest peaks were 
achieved by Dayan, et al.11 and Villar, et al.15 
respectively. 
A possible explanation for this is that the 
populations in these studies had high baseline 
DENV seropositivities (Table 1). High baseline 
seropositivity rates imply that a large portion 
of the population selected in these trials have 
had previous exposure to dengue virus. The 
baseline seropositivity in the test group of 
Dayan et, al.11 and Villar et al.15 was 69% and 
75.1%, respectively. This is much higher than 
the values reported by Leo et al (16.6%),16 
Amar-Singh et al.12 (44.9%), and Lanata et al.13 
(37.2%), all of whom had a relatively low peak 
antibody titer for all serologies. In previously 
seropositive patients, the dengue vaccine would 
elicit a secondary, instead of a primary, immune 
response. This explains the more enhanced peak 
GMT levels found in Dayan et al.11 and Villar, 
et al.15
From the safety and reactogenicity reports 
in all trials (Table 2), CYD-TDV vaccine is 
well tolerated and has a relatively good safety 
profile. As reported, all solicited injection-site 
or systemic adverse effects were similar in both 
test and control groups in all trials. Systemic 
and injection-site adverse effects were generally 
described as low grade in all trials. Unsolicited 
systemic adverse reactions occurred in similar 
rates between test and control groups in all 
studies, but were generally described to be 
unrelated to the injections.
The safety profile of the tested CYD-TDV 
is similar to that of other vaccines commonly 
used. The study by Villar et al.15 used DPT as 
the injection in control group (Table 1). From 
Table 2, we see that in this study, the rate of 
incidence of adverse effects is similar both in 
test and control groups, which implies that the 
safety profile of the CYD-TDV is similar to 
that of the DPT vaccine. The control groups of 
studies by Lanata, et al.13 and Leo et al.16 also 
used alternative vaccines. Hence, the similarities 
in the data for reactogenicity in control and test 
groups of these studies also implies a similar 
safety profile between the CYD-TDV and the 
vaccine they used for their control group.
Severe adverse effects were reported in all 
trials. However, they occurred in similar rates 
between control and test groups. The incidence 
of severe adverse effects is not unexpected as the 
trials lasted for a year in all studies, and SAEs 
were recorded throughout the trial period. In all 
of the trials except for Leo, et al.16, none of the 
cases of severe adverse effects were considered 
to be related to the vaccine in test groups. 
Three patients (0.3%) from Leo et al.16 study 
experienced relatively severe AEs (fever, rash 
and worsening of cervical spondylosis related to 
vaccination) such that they had to be withdrawn 
from the study.
Limitations of the Study
The efficacy measured in this systematic 
review is based solely on the induction of the 
immune system due to the dengue vaccine, 
which is expected to protect the subjects from 
the virus in the future. However, this systematic 
review does not provide concrete evidence on the 
long term efficacy of the vaccine. Several studies 
have been started on the long term efficacy of 
the vaccine, but they are still on-going as of 
July 2016.8
Future Research and Applications
The main purpose of developing the CYD-
TDV is to prevent the onset of symptomatic 
dengue disease. Since this systematic review 
shows that the CYD-TDV was effective and safe 
in children, therefore, it opens possibilities for 
further exploration of this vaccine in large-scale 
long term studies to assess its long-term efficacy 
in decreasing the prevalence of symptomatic 
dengue disease.
Additionally, from the discussion, it is seen 
that the high baseline dengue seropositivity 
rates in populations of Dayan et al.11 and Villar 
et al.15 expressed a stronger immune response 
to the CYD-TDV. It is plausible that this high 
baseline seropositivity is attributed to the fact 
that these studies were conducted in the highly 
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endemic regions of Latin America. Indonesia is 
also considered to be a highly endemic region for 
dengue virus. Hence, this review gives promise 
for high efficacy of this vaccine when applied 
in Indonesian populations.
CONCLUSION
In conclusion, this systematic review 
confirms that the efficacy (in terms of 
immunogenicity) and overall safety profile 
(in terms of reactogenicity) of CYD-TDV are 
satisfactory. Furthermore, this review supports 
the continued development and widespread 
use of CYD-TDV, in addition to current vector 
control methods, for the prevention of dengue 
disease in children and adolescents. CYD-TDV 
may be integrated into current vaccination 
programs to reduce incidence of dengue 
infections in areas with high burden of disease. 
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